Roivant Sciences

At the Wells Fargo healthcare conference Roivant reported positive clinical results: mosliciguat showed a placebo‑adjusted reduction in pulmonary vascular resistance of 56% in PH‑ILD and is moving into a phase III study, while LISRAYA (brepocitinib) was just approved for the treatment of dermatomyositis and initial prescriptions have been written. IMVT‑1402, an FcRn inhibitor, produced strong IgG suppression and promising signals across multiple autoimmune indications, including difficult‑to‑treat rheumatoid arthritis, Graves’ disease and myasthenia gravis. Management emphasized focused commercialization in orphan indications, possible near‑term catalysts, and noted regulatory and launch risks; the company was valued at just under $30bn at the time of the conference. » Plus sur de.investing.com

Roivant and Pulmovant announce they will present the phase-2 PHocus study of mosliciguat for pulmonary hypertension in interstitial lung disease on September 8, 2026, at the ERS Congress. Marc Humbert will present the results; Roivant will hold a conference call with webcast the same day at 8:00 a.m. ET, accessible on the investor site. Mosliciguat is an inhaled sGC activator; Roivant’s pipeline also includes LISRAYA (brepocitinib), approved by the FDA for dermatomyositis, and the anti‑FcRn antibody IMVT‑1402. » Plus sur de.investing.com

Roivant Sciences shares rose to an all-time high of $37.06 and are currently trading at $37.14, with a market capitalization of $26.19 billion. The stock has gained 206.52% over 12 months and 66.82% year-to-date; however, analysts view the stock as overvalued according to InvestingPro. In the first fiscal quarter, adjusted loss per share was $0.26 (better than the expected -$0.30), but revenue of $1.44 million fell short of forecasts. TD Cowen raised its price target from $41 to $50 and reiterated a "Buy" rating, citing potential catalysts in the second half of the year. » Plus sur de.investing.com